Cargando…

Clinical data from the real world: efficacy of Crizotinib in Chinese patients with advanced ALK-rearranged non-small cell lung cancer and brain metastases

Brain metastasis in non small cell lung cancer (NSCLC) patients is often considered as a terminal stage of advanced disease. Crizotinib is a small-molecule tyrosine kinase inhibitor (TKI) for ALK-rearranged NSCLC patients. Herein, we conducted a retrospective study to explore how Crizotinib affects...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xing, Puyuan, Wang, Shouzheng, Hao, Xuezhi, Zhang, Tongtong, Li, Junling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356690/ https://www.ncbi.nlm.nih.gov/pubmed/27835868 http://dx.doi.org/10.18632/oncotarget.13179

Ejemplares similares

Clinical features and outcomes of ALK rearranged non‐small cell lung cancer with primary resistance to crizotinib
por: Ma, Di, et al.
Publicado: (2019)

Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study
por: Yang, Guangjian, et al.
Publicado: (2019)

Favorable predictors for survival in advanced ALK‐positive non‐small cell lung cancer patients beyond crizotinib resistance
por: Xu, Haiyan, et al.
Publicado: (2019)

Impact of crizotinib on long-term survival of ALK-positive advanced non-small-cell lung cancer: A Chinese multicenter cohort study
por: Xing, Puyuan, et al.
Publicado: (2019)

Sequential therapy according to distinct disease progression patterns in advanced ALK-positive non-small-cell lung cancer after crizotinib treatment
por: Xu, Haiyan, et al.
Publicado: (2019)

Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center
por: Liu, Chang, et al.
Publicado: (2019)

Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations
por: Wang, Shouzheng, et al.
Publicado: (2019)

Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis
por: Xing, Puyuan, et al.
Publicado: (2022)

Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in EGFR-Mutated Lung Adenocarcinoma: A Real-World Study in Chinese Patients
por: Xu, Ziyi, et al.
Publicado: (2022)

Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement
por: Krawczyk, Paweł, et al.
Publicado: (2021)

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression
por: Chen, Rui-Lian, et al.
Publicado: (2018)

Dual drive coexistence of ALK rearrangement and KRAS mutation advanced lung adenocarcinoma and response to crizotinib
por: Zhu, You-Cai, et al.
Publicado: (2019)

Activity of crizotinib over choroidal metastases in Non-Small-Cell Lung Cancer (NSCLC)-ALK rearranged: a case report
por: Bearz, Alessandra, et al.
Publicado: (2014)

Real-World Data Of Osimertinib In Patients With Pretreated Non-Small Cell Lung Cancer: A Retrospective Study
por: Mu, Yuxin, et al.
Publicado: (2019)

Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China
por: Zou, Zihua, et al.
Publicado: (2021)

Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib
por: Mu, Yuxin, et al.
Publicado: (2019)

Real world study of regimen containing bevacizumab as first‐line therapy in Chinese patients with advanced non‐small cell lung cancer
por: Xing, Puyuan, et al.
Publicado: (2018)

Nab-paclitaxel in combination with Bevacizumab in patients with non-squamous non-small cell lung cancer after failure of at least one prior systemic regimen
por: Hao, Xuezhi, et al.
Publicado: (2020)

Alectinib as first-line treatment for advanced ALK-positive non-small cell lung cancer in the real-world setting: preliminary analysis in a Chinese cohort
por: Zou, Zihua, et al.
Publicado: (2022)

Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence
por: Wang, Yurong, et al.
Publicado: (2022)

Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicenter retrospective study
por: Zou, Zihua, et al.
Publicado: (2022)

Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancer
por: Hong, Xiangchan, et al.
Publicado: (2017)

Tumor volume dynamics and tumor growth rate in ALK-rearranged advanced non-small-cell lung cancer treated with crizotinib
por: Nishino, Mizuki, et al.
Publicado: (2020)

The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4–ALK Rearranged Non-small Cell Lung Cancer
por: Lin, Yen-Ting, et al.
Publicado: (2019)

EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes
por: Xu, Haiyan, et al.
Publicado: (2021)

Clinical effect of pemetrexed as the first‐line treatment in Chinese patients with advanced anaplastic lymphoma kinase‐positive non‐small cell lung cancer
por: Ma, Di, et al.
Publicado: (2016)

Real world study of the continuation of bevacizumab beyond disease progression after first‐line treatment containing bevacizumab in Chinese patients with advanced non‐small cell lung cancer
por: Xing, Puyuan, et al.
Publicado: (2018)

NCOA1–ALK: a novel ALK rearrangement in one lung adenocarcinoma patient responding to crizotinib treatment
por: Cao, Qi, et al.
Publicado: (2019)

Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib
por: Isla, Dolores, et al.
Publicado: (2020)

Anaplastic lymphoma kinase (ALK)-rearranged pulmonary pleomorphic carcinoma successfully treated with crizotinib
por: Lin, Liping, et al.
Publicado: (2018)

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
por: Mansfield, A. S., et al.
Publicado: (2022)

Real-life experience of ceritinib in crizotinib-pretreated ALK(+) advanced non-small cell lung cancer patients
por: Cadranel, Jacques, et al.
Publicado: (2018)

Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations
por: Li, Teng, et al.
Publicado: (2021)

Alectinib for choroidal metastasis in a patient with crizotinib-resistant ALK rearranged positive non-small cell lung cancer
por: Okuma, Yusuke, et al.
Publicado: (2015)

Effective Crizotinib schedule for an elderly patient with ALK rearranged non-small-cell lung cancer: a case report
por: Fukuizumi, Aya, et al.
Publicado: (2015)

Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK‐rearranged non‐small‐cell lung cancer
por: Song, Peng, et al.
Publicado: (2019)

Neoadjuvant crizotinib in ALK-rearranged inflammatory myofibroblastic tumor of the urinary bladder: A case report
por: Nagumo, Yoshiyuki, et al.
Publicado: (2018)

Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib
por: Liang, Hongge, et al.
Publicado: (2019)

Patients harboring ALK rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small-cell lung cancer: a case report
por: Zhu, You-cai, et al.
Publicado: (2017)

ALK(G1269A) mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor
por: Michels, Sebastian Y. F., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0p2d1b9pu5pfpnd04l1cfphr0b